• Be A Partner
  • Social Responsibility
    • Students Training
  • IR
    • Investor Relations
    • Financial Charts
    • Annual Reports
  • News
    • PRESS RELEASES
    • SOCIAL EVENTS
    • CONFERENCES
  • Careers
  • Covid-19
  • Report a side effect
  • Contact Us
    • Branches
  • Home
  • We are Eipico
    We are Eipico
    EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million.
    • Uniqueness
      • WHO Approval
      • Sterile products Area
      • Automatic Ampoules Inspection
      • Eipico Ophthalmology
      • Primary packaging materials
      • Restricted-access barrier system
      • Distribution Channel
    • Our History
    • Vision, Mission & Values
    • Chairman Message
    • Eipico Employees
    • Manufacturing Facilities
    • Media Library
  • Global
    Global
    EIPICO is ranked Number 1 in Egyptian Exports of Pharmaceutical Products, capturing 29% of Egypt’s Total Exports of Pharmaceutical Products, by Value.
    • Eipico Destination
  • Manufacturing Facilities
    Manufacturing Facilities
    EIPICO is the Leading Egyptian Pharmaceutical Company, in Production, by Units. It is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.
    • Factory 1
    • Factory 2
    • Factory 3 (Biotechnology)
    • Eiaco Factory
    • Batterjee Factory
    • EIPICO Plastic Factory
  • R&D And Quality
    R&D And Quality
    EIPICO provides High Quality Pharmaceutical Products at reasonable prices, thus assisting human healthcare improvement .
    • Quality Assurance
    • Quality Control
    • R&D
    • Regulatory Affairs
    • Global Accreditation
    • Track and Trace
  • Products
    Products
    EIPICO produces 400 Pharmaceutical Products covering 25 therapeutic classes and it is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.
    • Eipico Products
      • By Alphabet
  • Biotechnology
News Details
You are here : >>News >>Press Releases >News Details
 EIPICO to begin producing of “ Epifluovir “ – favipiravir- for covid-19 patients and manufacturing ” Remicovir “ - remdesivir soon. 
 
 
Dr. Ahmed Kelani - Chairman and Managing Director of EIPICO Pharmaceutical Industries Company, said that the company – today - received an approval from the Ministry of Health to manufacture ” Remicovir “ - remdesivir - for the treatment of Corona Virus- in the first week of August and to be supplied by the company- in the second half of August.

Dr. Ahmed Kelani - during a telephone interference with TV program " Al Hekaya " broadcasting through the satellite "MBC Egypt" - on Monday evening- added that the company has produced the Japanese drug - known internationally as "Avigan". ( under the name of “ Epifluovir” ).

The product already is in the company stores and waiting for MOH instructions to provide it to hospitals at a subsidized price.

Dr. Kelani pointed out that the company has provided large quantities of medicines used according to Ministry of Health Protocol for the treatment of Corona Virus. He Also pointing out that EIPICO had suppled hospitals with large quantities of the drug used in the treatment of "C virus".

He continued that: the company seeks to reach high quality of medicines, transferring international technology, and manufacturing the raw material in Egypt, instead of importing it.
 

July 28nd, 2020







WE ARE EIPICO

  • Uniqueness
  • Our History
  • Vision, Mission & Values
  • Chairman Message
  • Eipico Employees

Manufacturing Facilities

  • Factory 1
  • Factory 2
  • Factory 3
  • Eiaco Factory
  • Batterjee Factory
  • Plastic Factory

Products

  • Eipico Product
  • Eipico Products By Alphabet

Contact Us

EIPICO, Tenth of Ramadan City - 1st Industrial Zone B1, Egypt.

Telephone : +20554499199
Fax : +20554499306

eipico@eipico.com.eg

Back to top
Powered by EIPICO Team
    Visitors Count : 440830